Aggressive B-cell lymphomas: female BMI tied to R-CHOP-14 outcomes

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • In women aged 60 years with aggressive B-cell lymphomas treated with R-CHOP-14 (rituximab + cyclophosphamide, doxorubicin, vincristine, and prednisolone at 14-day intervals), obesity was a risk factor for inferior event-free survival (EFS), PFS, and OS.

Why this matters

  • Dat...